EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation

Xiao Han iD, Jun Zhang iD, Pingchang Guo iD, Junshun Chang iD, Bing Liu iD, Xin Diao iD, Ping Wu iD, Sheng He iD, Hua Wei iD, Wenjuan Dai iD, Yu Hong iD, Yuwen Chen iD und 4 weitere

Reviews in Cardiovascular Medicine · 20.10.2026 · 27 (10)

DOI: 10.31083/rcm51179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 20.10.2026. Verfasst von Xiao Han und 15 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, 030000 Taiyuan, Shanxi, China. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project, the Innovation Plan for Postgraduate Education in Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium–glucose cotransporter 2 (SGLT2) inhibitors have attracted considerable attention owing to their unexpected cardioprotective benefits in addition to glycemic control. Indeed, these inhibitors have been reported to exert anti-fibrotic effects and ameliorate NACHT, leucine-rich repeat (LRR), and pyrin domain-containing protein 3 (NLRP3)-dependent inflammation. However, whether SGLT2 inhibitors (SGLT2is) attenuate post-infarction myocardial fibrosis by suppressing NLRP3-dependent signaling remains unclear. Thus, this study aimed to investigate the mechanisms through which the SGLT2is dapagliflozin (DAPA) mitigates post-infarction myocardial fibrosis, with particular emphasis on the modulation of NLRP3-dependent signaling.

Methods

Male Sprague-Dawley rats were used to establish a myocardial infarction (MI) model via left coronary artery ligation and were treated with DAPA (1 mg/kg/day). Cardiac magnetic resonance imaging was performed to evaluate cardiac function and remodeling. Serial 18F-fibroblast activation protein inhibitor-74 (18F-FAPI-74) positron emission tomography (PET) was used to track temporal changes in cardiac fibroblast (CF) activation. Myocardial fibrosis and NLRP3-dependent signaling were assessed ex vivo. The effects of DAPA on NLRP3-dependent signaling, fibroblast proliferation, phenotypic transition, and collagen synthesis were determined in vitro using cardiac fibroblasts (CFs) stimulated with lipopolysaccharide.

Results

Compared with untreated MI rats, MI rats treated with DAPA exhibited significantly lower left ventricular (LV) end-systolic volume, LV end-diastolic volume, and LV mass, along with improved LV ejection fraction (57.6 ± 2.4% vs. 54.4 ± 2.1% in the MI group; p = 0.011). LV fibrosis was reduced in DAPA-treated MI rats (20.1 ± 1.9% vs. 31.1 ± 4.0% in the MI group; p = 0.0026), and fibrosis markers were significantly downregulated. In vivo 18F-FAPI-74 PET revealed that DAPA suppressed CF activation, as demonstrated by significantly reduced 18F-FAPI-74 uptake in the infarcted region. In infarcted cardiac tissue, DAPA inhibited the expression of the NLRP3 inflammasome, interleukin-1 beta (IL-1β), and interleukin-18 (IL-18). CF experiments performed in vitro showed that DAPA inhibited the nuclear factor kappa B (NF-κB)/NLRP3 pathway and attenuated CF proliferation, phenotypic transition, and collagen synthesis.

Conclusions

By suppressing CF activation, DAPA improved myocardial fibrosis, adverse LV remodeling, and cardiac function post-MI, in association with inhibition of the NF-κB/NLRP3 pathway. 18F-FAPI-74 PET enabled non-invasive visualization of the anti-fibrotic effects of DAPA post-MI and may serve as a tool to monitor anti-fibrotic treatment efficacy after MI.

Schlagwörter

Stichwörter der Autor:innen

NLR family, pyrin domain-containing 3 proteinfibroblast activation protein alphafibroblastsmyocardial infarctionsodium-glucose transporter 2ventricular remodeling

Autor:innen und Institutionen

  • Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, 030000 Taiyuan, Shanxi, China.
  • Department of Nuclear Medicine, First Hospital of Shanxi Medical University, 030000 Taiyuan, Shanxi, China.
  • Department of Cardiology, First Hospital of Shanxi Medical University, 030000 Taiyuan, Shanxi, China.
  • Department of Radiology, First Hospital of Shanxi Medical University, 030000 Taiyuan, Shanxi, China.
  • Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Shanxi Medical University, 030000 Taiyuan, Shanxi, China.

ORCID-Profile: Xiao Han, Jun Zhang, Pingchang Guo, Junshun Chang, Bing Liu, Xin Diao, Ping Wu, Sheng He, Hua Wei, Wenjuan Dai, Yu Hong, Yuwen Chen, Li Li, Ruonan Wang, Zhifang Wu, Sijin Li

Förderung

  • the National Natural Science Foundation of China
  • the Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project
  • the Innovation Plan for Postgraduate Education in Shanxi Province

Zitieren

APA

Han, X., Zhang, J., Guo, P., Chang, J., Liu, B., Diao, X., Wu, P., He, S., Wei, H., Dai, W., Hong, Y., Chen, Y., Li, L., Wang, R., Wu, Z., & Li, S. (2026). Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation. Reviews in Cardiovascular Medicine, 27(10). https://doi.org/10.31083/rcm51179

Vancouver

Han X, Zhang J, Guo P, Chang J, Liu B, Diao X, et al. Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation. Reviews in Cardiovascular Medicine. 2026;27(10). doi:10.31083/rcm51179

BibTeX
@article{Han2026,
  author = {Han, Xiao and Zhang, Jun and Guo, Pingchang and Chang, Junshun and Liu, Bing and Diao, Xin and Wu, Ping and He, Sheng and Wei, Hua and Dai, Wenjuan and Hong, Yu and Chen, Yuwen and Li, Li and Wang, Ruonan and Wu, Zhifang and Li, Sijin},
  title = {Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2026},
  volume = {27},
  number = {10},
  doi = {10.31083/rcm51179}
}
Kostenlos starten →